Kala Pharmaceuticals appoints Marjan Farid, M.D. to board of directors

KALA BIO, Inc.

Dr. Farid appointed as Class I director effective Oct. 31, 2022; term expires at 2024 annual meeting.
She joins the Nominating and Corporate Governance Committee.
Received a one-time stock option to purchase 1,600 shares at $6.35 per share (closing price on appointment date).
Option vests 1/3 on first anniversary, then monthly over three years; standard indemnification agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Marjan Farid, M.D.

Class I director

KALA · KALA BIO, Inc.

Effective: 2022-10-31
Filed: November 1, 2022, 7:59 PM ET

On October 31,, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of Kala Pharmaceuticals, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Marjan Farid, M.D. as a member of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Marjan Farid, M.D. was appointed as Class I director at KALA BIO, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

On October 31,, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of Kala Pharmaceuticals, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Marjan Farid, M.D. as a member of the Board, effective immediately.

View on SEC.gov

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-015785

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.